Innovative Investments Transform Life Sciences and Music Streaming

Kotak Alternate Asset Managers announced on Monday a significant investment of Rs 20 crore into Cellogen Therapeutics, a company backed by NATCO Pharma. This funding, facilitated through Kotak Life Sciences Fund I, is earmarked for the advancement of CAR'T clinical programs and the expansion of Cellogen's gene therapy pipeline.

In a separate development in the music industry, Damroo, a burgeoning music streaming platform, has successfully raised Rs 5 crore from Hindustan Times. This injection of capital aims to fuel the platform's objectives of expanding artist development and audience reach, as well as enhancing monetization strategies and industry support initiatives.

Both investments reflect a growing trend of capital influx in dynamic sectors, with a focus on technological advancement and cultural expansion.

(With inputs from agencies.)